QUADRAMET
Total Payments
$2.3M
Transactions
64
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $482,945 | 3 | 0 |
| 2021 | $675,325 | 38 | 0 |
| 2020 | $963,587 | 20 | 0 |
| 2019 | $218,460 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 64 | 100.0% |
Top Doctors Receiving Payments for QUADRAMET
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Columbia, MO | $2.3M | 64 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 0
- Transactions 64
About QUADRAMET
QUADRAMET is a drug associated with $2.3M in payments to 0 healthcare providers, recorded across 64 transactions in the CMS Open Payments database. The primary manufacturer is Lantheus Medical Imaging, Inc..
Payment data is available from 2019 to 2022. In 2022, $482,945 was paid across 3 transactions to 0 doctors.
The most common payment nature for QUADRAMET is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.3M, 100.0% of total).